Similarly,
Efluelda returns winter 2025-2026 new: Furthermore. Similarly,
Efluelda returns winter 2025-2026:
The Sanofi laboratory has redesigned an approval and reimbursement file for this new season. Therefore, Last May. Meanwhile. the High Authority for Health (HAS) recommended the preferential use of Efluelda and Fluad influenza vaccines, in people aged 65 and over. Therefore, The publication in the Official Journal of July 23 completes this recommendation.
A vaccine for those over 65 – Efluelda returns winter 2025-2026
Efluelda is a high -dose trivalent vaccine. Consequently, containing four times more antigens than a standard vaccine. It is primarily intended for seniors, more vulnerable to the complications of the flu, while maintaining a good tolerance profile.
Already used in previous campaigns. it has proven its effectiveness: a study based on data in the national health data system (2021-2022 season) has. shown a reduction of approximately 23 % of hospitalizations compared to standard vaccines.
Sanofi also anticipated efluelda returns winter 2025-2026 new its production in March 2025, to guarantee its availability upstream of the efluelda returns winter 2025-2026 campaign.
A pricing compromise after withdrawal from the market
Efluelda had been withdrawn from the French market for lack of agreement. with the Economic Committee for Health Products (CEPS) on its price. A compromise has since been found. According to APM news“Efluelda obtained a PFHT of 20 euros, 23 % less than that of December 2020. The Public Prize TTC stands at 23.97 euros. Note that discounts can be applied, making the real price higher than that displayed.
On the medico-economic level. the vaccine saw its revalued ASMR. going from a level V to IV, a minor improvement in the medical service rendered in those over 65. It will be 100 % reimbursed for populations defined by these vaccination recommendations. via a health insurance management voucher, such as other influenza vaccines.
Fluad: recommended but always absent efluelda returns winter 2025-2026 new from the market
Another vaccine recommended for those over 65: Fluad, from the Vifor laboratory (CSL group). efluelda returns winter 2025-2026 It benefits from the same tariff and reimbursement conditions as Efluelda. However, Fluad was never marketed in France, despite European authorization dating from the late 1990s.
Further reading: New medical pricing, a risk for breast cancer screening – RTS.CH – Women’s well-being: IRD initiates an evening-debate on breast cancer – The more dangerous acral melanoma than we thought! – Nine benzodiazepines of summary on the drug list | The daily life of the pharmacist – Voyage and measles – miscarriage – ADHD and family life.
Further reading: A 50 cents sensor can detect cancer or HIV – Resilience at work: the secrets of the brain for better recovery – End of monitoring of a bleast in measles in southwest Ontario – These questions that everyone is asking about the sun in summer – Vape: new confirmation of its substitution function.
